Cross-Sectional Analysis of Insurance Coverage for Lymphedema Treatments in the United States
JAMA Surgery · 2023
DOI: 10.1001/jamasurg.2023.2017 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift JAMA Surgery, 2023. Verfasst von Jeremy V Lynn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Health Promotion, Lymphedema. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Lymphedema is a debilitating condition that affects approximately 1 in 1000 individuals in the United States. Complete decongestive therapy is currently the standard of care, and innovative surgical techniques have demonstrated potential to further improve outcomes. Despite the growing armamentarium of treatment options, a large proportion of patients with lymphedema continue to struggle because of limited access to care.
Objective
To define the current state of insurance coverage for lymphedema treatments in the United States. Design, Setting, and Participants A cross-sectional analysis of insurance reimbursement for lymphedema treatments in 2022 was designed. The top 3 insurance companies per state based on market share and enrollment data maintained by the Kaiser Family Foundation were included. Established medical policies were gathered from insurance company websites and phone interviews, and descriptive statistics were performed. Main Outcomes and Measures Treatments of interest included nonprogrammable pneumatic compression, programmable pneumatic compression, surgical debulking, and physiologic procedures. Primary outcomes included level of coverage and criteria for coverage.
Results
This study included 67 health insurance companies representing 88.7% of the US market share. Most insurance companies offered coverage for nonprogrammable (n = 55, 82.1%) and programmable (n = 53, 79.1%) pneumatic compression. However, few insurance companies offered coverage for debulking (n = 13, 19.4%) or physiologic (n = 5, 7.5%) procedures. Geographically, the lowest rates of coverage were seen in the West, Southwest, and Southeast. Conclusions and Relevance This study suggests that in the United States, less than 12% of individuals with health insurance, and even fewer patients without health insurance, have access to pneumatic compression and surgical treatments for lymphedema. The stark inadequacy of insurance coverage must be addressed through research and lobbying efforts to mitigate health disparities and promote health equity among patients with lymphedema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, University of Michigan, Ann Arbor.
- Central Michigan University College of Medicine, Saginaw.
Zitieren
APA
Lynn, J. V., Hespe, G. E., Akhter, M. F., David, C. M., Kung, T. A., & Myers, P. L. (2023). Cross-Sectional Analysis of Insurance Coverage for Lymphedema Treatments in the United States. JAMA Surgery. https://doi.org/10.1001/jamasurg.2023.2017
Vancouver
Lynn JV, Hespe GE, Akhter MF, David CM, Kung TA, Myers PL. Cross-Sectional Analysis of Insurance Coverage for Lymphedema Treatments in the United States. JAMA Surgery. 2023. doi:10.1001/jamasurg.2023.2017
BibTeX
@article{Lynn2023,
author = {Lynn, Jeremy V and Hespe, Geoffrey E and Akhter, Maheen F and David, Christelle M and Kung, Theodore A and Myers, Paige L},
title = {Cross-Sectional Analysis of Insurance Coverage for Lymphedema Treatments in the United States},
journal = {JAMA Surgery},
year = {2023},
doi = {10.1001/jamasurg.2023.2017}
}
EUVIMED